论文部分内容阅读
目的对微生态制剂干预肠易激综合征患者的疗效进行系统性分析,指导临床用药。方法联机检索Medline、维普、万方数据库、CNKI、CBMdisc中微生态制剂治疗肠易激综合征疗效的随机对照临床试验,对文献质量进行严格评价和资料提取,对符合质量标准的RCT进行Meta分析。结果共有7项研究符合入选标准,其中5项研究提示微生态制剂干预肠易激综合征患者疗效不优于安慰剂,2项研究认为微生态制剂有效改善患者的临床症状,荟萃结果表明微生态制剂可以有效缓解肠易激综合征临床症状[OR(95%CI):1.66(1.27,2.18)]。结论微生态制剂可以有效缓解肠易激综合征临床症状。
Objective To systematically analyze the efficacy of probiotics in the treatment of patients with irritable bowel syndrome and guide the clinical use of drugs. Methods A randomized controlled clinical trial on the efficacy of probiotics in treatment of irritable bowel syndrome (IBS) in Medline, VIP, Wanfang database, CNKI and CBMdisc was performed online. The quality of the literature was critically evaluated and the data were extracted. The Meta-analysis . Results A total of seven studies met the inclusion criteria. Five of the studies suggested that the efficacy of probiotics in the treatment of irritable bowel syndrome was not superior to that of placebo. Two studies suggested that probiotics could effectively improve the clinical symptoms of patients. Meta-analysis showed that the micro- The formulation can effectively alleviate the clinical symptoms of irritable bowel syndrome [OR (95% CI): 1.66 (1.27, 2.18)]. Conclusion The probiotics can effectively relieve the clinical symptoms of irritable bowel syndrome.